Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation

Ching Yih Lin, Yu Feng Tian, Li Ching Wu, Li Tzong Chen, Li Ching Lin, Chung Hsi Hsing, Sung Wei Lee, Ming Jen Sheu, Hao Hsien Lee, Yu Hui Wang, Yow Ling Shiue, Wen Ren Wu, Hsuan Ying Huang, Han Ping Hsu, Chien Feng Li, Shang Hung Chen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalJournal of Clinical Pathology
Volume65
Issue number8
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Fingerprint

Rectal Neoplasms
Neoadjuvant Therapy
Therapeutics
Neoplasms
Histone Chaperones
Neoplasm Metastasis
Chromatin Assembly and Disassembly
Survival
Nuclear Proteins
Disease-Free Survival
Adenosine Triphosphatases
Carcinoma
Biopsy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rsf-1 expression in rectal cancer : With special emphasis on the independent prognostic value after neoadjuvant chemoradiation. / Lin, Ching Yih; Tian, Yu Feng; Wu, Li Ching; Chen, Li Tzong; Lin, Li Ching; Hsing, Chung Hsi; Lee, Sung Wei; Sheu, Ming Jen; Lee, Hao Hsien; Wang, Yu Hui; Shiue, Yow Ling; Wu, Wen Ren; Huang, Hsuan Ying; Hsu, Han Ping; Li, Chien Feng; Chen, Shang Hung.

In: Journal of Clinical Pathology, Vol. 65, No. 8, 08.2012, p. 687-692.

Research output: Contribution to journalArticle

Lin, CY, Tian, YF, Wu, LC, Chen, LT, Lin, LC, Hsing, CH, Lee, SW, Sheu, MJ, Lee, HH, Wang, YH, Shiue, YL, Wu, WR, Huang, HY, Hsu, HP, Li, CF & Chen, SH 2012, 'Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation', Journal of Clinical Pathology, vol. 65, no. 8, pp. 687-692. https://doi.org/10.1136/jclinpath-2012-200786
Lin, Ching Yih ; Tian, Yu Feng ; Wu, Li Ching ; Chen, Li Tzong ; Lin, Li Ching ; Hsing, Chung Hsi ; Lee, Sung Wei ; Sheu, Ming Jen ; Lee, Hao Hsien ; Wang, Yu Hui ; Shiue, Yow Ling ; Wu, Wen Ren ; Huang, Hsuan Ying ; Hsu, Han Ping ; Li, Chien Feng ; Chen, Shang Hung. / Rsf-1 expression in rectal cancer : With special emphasis on the independent prognostic value after neoadjuvant chemoradiation. In: Journal of Clinical Pathology. 2012 ; Vol. 65, No. 8. pp. 687-692.
@article{949059b84f774b3cb5d09e3a010a554a,
title = "Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation",
abstract = "Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7{\%}), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p",
author = "Lin, {Ching Yih} and Tian, {Yu Feng} and Wu, {Li Ching} and Chen, {Li Tzong} and Lin, {Li Ching} and Hsing, {Chung Hsi} and Lee, {Sung Wei} and Sheu, {Ming Jen} and Lee, {Hao Hsien} and Wang, {Yu Hui} and Shiue, {Yow Ling} and Wu, {Wen Ren} and Huang, {Hsuan Ying} and Hsu, {Han Ping} and Li, {Chien Feng} and Chen, {Shang Hung}",
year = "2012",
month = "8",
doi = "10.1136/jclinpath-2012-200786",
language = "English",
volume = "65",
pages = "687--692",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Rsf-1 expression in rectal cancer

T2 - With special emphasis on the independent prognostic value after neoadjuvant chemoradiation

AU - Lin, Ching Yih

AU - Tian, Yu Feng

AU - Wu, Li Ching

AU - Chen, Li Tzong

AU - Lin, Li Ching

AU - Hsing, Chung Hsi

AU - Lee, Sung Wei

AU - Sheu, Ming Jen

AU - Lee, Hao Hsien

AU - Wang, Yu Hui

AU - Shiue, Yow Ling

AU - Wu, Wen Ren

AU - Huang, Hsuan Ying

AU - Hsu, Han Ping

AU - Li, Chien Feng

AU - Chen, Shang Hung

PY - 2012/8

Y1 - 2012/8

N2 - Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p

AB - Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods: Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results: Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced posttreatment tumour status (T3, T4, p

UR - http://www.scopus.com/inward/record.url?scp=84864557910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864557910&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2012-200786

DO - 10.1136/jclinpath-2012-200786

M3 - Article

C2 - 22569540

AN - SCOPUS:84864557910

VL - 65

SP - 687

EP - 692

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -